Bacterial Vaccines Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Bacterial Vaccines Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type (Pertussis (Whooping Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines, Cholera Vaccines, Shigellosis Vaccines, Others), By Patient Age Group (Pediatric Vaccines (Infants, Children), Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines), By Distribution Channel (Government Agencies and Programs, Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, Others) , By Route of Administration (Injectable Vaccines, Oral Vaccines, Nasal Vaccines), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Bacterial Vaccines Market is projected to expand from USD 7.19 billion in 2025 to USD 10.94 billion by 2031, achieving a 7.25% CAGR. Bacterial vaccines are biological agents designed to stimulate active immunity against specific bacterial infections. This growth is driven by the increasing incidence of infectious diseases like meningitis and pneumonia, alongside strong government immunization initiatives, which contributed to an 85% global coverage for the DTP3 vaccine in 2024 according to WHO and UNICEF. However, a major impediment is the intricate and costly cold chain logistics required for vaccine storage and distribution, which often limits market access in developing countries where the disease burden is most severe.
Market Driver
A key driver for the bacterial vaccines market is the growing threat of antimicrobial resistance (AMR), positioning vaccines as crucial tools to reduce antibiotic dependence by preventing infections like pneumonia and meningitis. The WHO's October 2024 report indicated that vaccines against 23 pathogens could annually cut antibiotic doses by 2.5 billion, underscoring their essential role in antimicrobial stewardship and national health security. Simultaneously, technological progress in conjugate and recombinant vaccines is broadening market potential through improved serotype coverage and durable immunity. High-valency formulations offer wider protection against various bacterial strains, as demonstrated by Merck's June 2024 FDA approval of a 21-valent conjugate vaccine for pneumococcal disease. These innovations are bolstered by investments like Gavi's 2024 launch of the African Vaccine Manufacturing Accelerator, a US$1 billion initiative to foster vaccine production in emerging markets.
Market Challenge
The global bacterial vaccines market faces a significant restraint due to the stringent cold chain requirements. These vaccines demand precise temperature control throughout their journey, from manufacturing to patient, necessitating specialized storage and transport. In regions with poor infrastructure, ensuring temperature integrity is technically challenging and financially burdensome, raising operational costs and reducing profit margins. This economic strain hinders expansion into price-sensitive developing markets, where logistical overheads diminish ROI. Such infrastructure rigidities impede market penetration, leading to supply chain inefficiencies, vaccine wastage, and restricted access in areas with high disease incidence. Gavi's 2024 report on 10.2 million zero-dose children in lower-income countries exemplifies these persistent access barriers.
Market Trends
The market is significantly influenced by two key trends. Firstly, structural vaccinology combined with AI for antigen discovery is transforming R&D by enabling precise computational design of bacterial immunogens, surpassing traditional empirical approaches. Google DeepMind's AlphaFold 3, for instance, boosts biomolecular interaction prediction accuracy by 50%, accelerating the identification of bacterial protein targets and reducing preclinical attrition rates. Secondly, there's a growing focus on maternal immunization research for Group B Streptococcus (GBS) to decrease neonatal mortality via vertical immunity. This aims to overcome the limitations of inaccessible intrapartum antibiotic prophylaxis in low-resource settings. MinervaX's September 2024 manufacturing scale-up for GBS vaccine trials highlights the sector's commitment to establishing maternal vaccination as a standard for preventing severe neonatal bacterial infections.
Key Market Players
* Pfizer Inc.
* GSK plc
* Novartis AG
* Mylan N.V.
* Sanofi SA
* Boehringer Ingelheim International GmbH.
* Merck & Co., Inc.
* F. Hoffmann-La Roche Ltd.
* Bristol-Myers Squibb Company
* Bharat Biotech International Ltd
* Serum Institute of India Pvt. Ltd
Report Scope
In this report, the Global Bacterial Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Bacterial Vaccines Market, By Vaccine Type
* Pertussis (Whooping Cough) Vaccines
* Tetanus Vaccines
* Diphtheria Vaccines
* Pneumococcal Vaccines
* Meningococcal Vaccines
* Typhoid Vaccines
* Tuberculosis (TB) Vaccines
* Cholera Vaccines
* Shigellosis Vaccines
* Others
# Bacterial Vaccines Market, By Patient Age Group
* Pediatric Vaccines
* Adolescent Vaccines
* Adult Vaccines
* Geriatric Vaccines
# Bacterial Vaccines Market, By Distribution Channel
* Government Agencies and Programs
* Hospitals and Clinics
* Retail Pharmacies
* Online Pharmacies
* Others
# Bacterial Vaccines Market, By Route of Administration
* Injectable Vaccines
* Oral Vaccines
* Nasal Vaccines
# Bacterial Vaccines Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Vaccines Market.
Available Customizations:
Global Bacterial Vaccines Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Bacterial Vaccines Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Vaccine Type (Pertussis (Whooping Cough) Vaccines, Tetanus Vaccines, Diphtheria Vaccines, Pneumococcal Vaccines, Meningococcal Vaccines, Typhoid Vaccines, Tuberculosis (TB) Vaccines, Cholera Vaccines, Shigellosis Vaccines, Others)
5.2.2. By Patient Age Group (Pediatric Vaccines (Infants, Children), Adolescent Vaccines, Adult Vaccines, Geriatric Vaccines)
5.2.3. By Distribution Channel (Government Agencies and Programs, Hospitals and Clinics, Retail Pharmacies, Online Pharmacies, Others)
5.2.4. By Route of Administration (Injectable Vaccines, Oral Vaccines, Nasal Vaccines)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Bacterial Vaccines Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Vaccine Type
6.2.2. By Patient Age Group
6.2.3. By Distribution Channel
6.2.4. By Route of Administration
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Bacterial Vaccines Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Vaccine Type
6.3.1.2.2. By Patient Age Group
6.3.1.2.3. By Distribution Channel
6.3.1.2.4. By Route of Administration
6.3.2. Canada Bacterial Vaccines Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Vaccine Type
6.3.2.2.2. By Patient Age Group
6.3.2.2.3. By Distribution Channel
6.3.2.2.4. By Route of Administration
6.3.3. Mexico Bacterial Vaccines Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Vaccine Type
6.3.3.2.2. By Patient Age Group
6.3.3.2.3. By Distribution Channel
6.3.3.2.4. By Route of Administration
7. Europe Bacterial Vaccines Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Vaccine Type
7.2.2. By Patient Age Group
7.2.3. By Distribution Channel
7.2.4. By Route of Administration
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Bacterial Vaccines Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Vaccine Type
7.3.1.2.2. By Patient Age Group
7.3.1.2.3. By Distribution Channel
7.3.1.2.4. By Route of Administration
7.3.2. France Bacterial Vaccines Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Vaccine Type
7.3.2.2.2. By Patient Age Group
7.3.2.2.3. By Distribution Channel
7.3.2.2.4. By Route of Administration
7.3.3. United Kingdom Bacterial Vaccines Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Vaccine Type
7.3.3.2.2. By Patient Age Group
7.3.3.2.3. By Distribution Channel
7.3.3.2.4. By Route of Administration
7.3.4. Italy Bacterial Vaccines Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Vaccine Type
7.3.4.2.2. By Patient Age Group
7.3.4.2.3. By Distribution Channel
7.3.4.2.4. By Route of Administration
7.3.5. Spain Bacterial Vaccines Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Vaccine Type
7.3.5.2.2. By Patient Age Group
7.3.5.2.3. By Distribution Channel
7.3.5.2.4. By Route of Administration
8. Asia Pacific Bacterial Vaccines Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Vaccine Type
8.2.2. By Patient Age Group
8.2.3. By Distribution Channel
8.2.4. By Route of Administration
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Bacterial Vaccines Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Vaccine Type
8.3.1.2.2. By Patient Age Group
8.3.1.2.3. By Distribution Channel
8.3.1.2.4. By Route of Administration
8.3.2. India Bacterial Vaccines Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Vaccine Type
8.3.2.2.2. By Patient Age Group
8.3.2.2.3. By Distribution Channel
8.3.2.2.4. By Route of Administration
8.3.3. Japan Bacterial Vaccines Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Vaccine Type
8.3.3.2.2. By Patient Age Group
8.3.3.2.3. By Distribution Channel
8.3.3.2.4. By Route of Administration
8.3.4. South Korea Bacterial Vaccines Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Vaccine Type
8.3.4.2.2. By Patient Age Group
8.3.4.2.3. By Distribution Channel
8.3.4.2.4. By Route of Administration
8.3.5. Australia Bacterial Vaccines Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Vaccine Type
8.3.5.2.2. By Patient Age Group
8.3.5.2.3. By Distribution Channel
8.3.5.2.4. By Route of Administration
9. Middle East & Africa Bacterial Vaccines Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Vaccine Type
9.2.2. By Patient Age Group
9.2.3. By Distribution Channel
9.2.4. By Route of Administration
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Bacterial Vaccines Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Vaccine Type
9.3.1.2.2. By Patient Age Group
9.3.1.2.3. By Distribution Channel
9.3.1.2.4. By Route of Administration
9.3.2. UAE Bacterial Vaccines Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Vaccine Type
9.3.2.2.2. By Patient Age Group
9.3.2.2.3. By Distribution Channel
9.3.2.2.4. By Route of Administration
9.3.3. South Africa Bacterial Vaccines Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Vaccine Type
9.3.3.2.2. By Patient Age Group
9.3.3.2.3. By Distribution Channel
9.3.3.2.4. By Route of Administration
10. South America Bacterial Vaccines Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Vaccine Type
10.2.2. By Patient Age Group
10.2.3. By Distribution Channel
10.2.4. By Route of Administration
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Bacterial Vaccines Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Vaccine Type
10.3.1.2.2. By Patient Age Group
10.3.1.2.3. By Distribution Channel
10.3.1.2.4. By Route of Administration
10.3.2. Colombia Bacterial Vaccines Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Vaccine Type
10.3.2.2.2. By Patient Age Group
10.3.2.2.3. By Distribution Channel
10.3.2.2.4. By Route of Administration
10.3.3. Argentina Bacterial Vaccines Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Vaccine Type
10.3.3.2.2. By Patient Age Group
10.3.3.2.3. By Distribution Channel
10.3.3.2.4. By Route of Administration
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Bacterial Vaccines Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Pfizer Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. GSK plc
15.3. Novartis AG
15.4. Mylan N.V.
15.5. Sanofi SA
15.6. Boehringer Ingelheim International GmbH.
15.7. Merck & Co., Inc.
15.8. F. Hoffmann-La Roche Ltd.
15.9. Bristol-Myers Squibb Company
15.10. Bharat Biotech International Ltd
15.11. Serum Institute of India Pvt. Ltd
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們